ERAS and cancer: These have been proposed as alternatives to the long-term rodent cancer bioassay, particularly where subsequent evaluations have shown the assay(s) to be robust, which is the case for the in vivo transgenic Hras2 mouse model, for example (Jacobs and Brown 2015).